- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00033904
Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective:
- The primary objective of this study is to determine whether subjects randomized to receive adjuvant HSPPC-96 after surgical resection of locally advanced renal cell carcinoma at high risk of recurrence, have improved recurrence-free survival as compared to subjects with no adjuvant treatment.
Secondary Objective:
- Determine whether subjects randomized to receive HSPPC-96 have improved survival as compared to subjects with no adjuvant treatment.
- Further characterize the safety profile of HSPPC-96.
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria
-
-
-
-
-
Kortrijk, Belgium
-
Liege, Belgium
-
-
-
-
-
Quebec, Canada
-
-
Alberta
-
Calgary, Alberta, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
Victoria, British Columbia, Canada
-
-
Ontario
-
London, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
-
-
-
-
Lille, France
-
Strasbourg, France
-
Toulouse Cedex, France
-
Villejuif Cedex, France
-
-
-
-
-
Haifa, Israel
-
Holon, Israel
-
Jerusalem, Israel
-
Tel-Hashomer, Israel
-
-
Zerifin
-
Beer-Yaacob, Zerifin, Israel
-
-
-
-
-
Oslo, Norway
-
Stavanger, Norway
-
-
-
-
-
Bialystok, Poland
-
Gdansk, Poland
-
Kielce, Poland
-
Krakow, Poland
-
Lublin, Poland
-
Szczecin, Poland
-
Warsaw, Poland
-
-
-
-
-
Barcelona, Spain
-
Madrid, Spain
-
Valencia, Spain
-
-
-
-
-
Gothenburg, Sweden
-
Lund, Sweden
-
Umea, Sweden
-
Uppsala, Sweden
-
-
-
-
-
Bristol, United Kingdom
-
London, United Kingdom
-
-
-
-
Alaska
-
Anchorage, Alaska, United States
-
-
Arizona
-
Tucson, Arizona, United States
-
-
California
-
Los Angeles, California, United States
-
San Francisco, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
Connecticut
-
Farmington, Connecticut, United States
-
-
Florida
-
Boca Raton, Florida, United States
-
Miami, Florida, United States
-
Tampa, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
Maywood, Illinois, United States
-
-
Iowa
-
Iowa City, Iowa, United States
-
-
Kansas
-
Kansas City, Kansas, United States
-
-
Louisiana
-
Gretna, Louisiana, United States, 70056
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
-
-
Missouri
-
St. Louis, Missouri, United States
-
-
New Mexico
-
Albuquerque, New Mexico, United States
-
-
New York
-
Manhasset, New York, United States
-
New York City, New York, United States
-
Rochester, New York, United States
-
-
North Carolina
-
Charlotte, North Carolina, United States
-
Winston-Salem, North Carolina, United States
-
-
Ohio
-
Cincinatti, Ohio, United States
-
Cleveland, Ohio, United States
-
Columbus, Ohio, United States
-
-
Oregon
-
Eugene, Oregon, United States
-
Portland, Oregon, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
-
Tennessee
-
Knoxville, Tennessee, United States
-
Nashville, Tennessee, United States
-
-
Texas
-
Ft. Worth, Texas, United States
-
Houston, Texas, United States
-
-
Vermont
-
South Burlington, Vermont, United States
-
-
Virginia
-
Richmond, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Pre-Surgery Inclusion Criteria:
- Primary-intact resectable renal cell cancer, without known distant metastasis and be scheduled to have surgery with curative intent;
- Tumor size greater than or equal to 5 cm OR macroscopic nodes OR renal vein thrombus OR vena cava thrombus by radiologic evaluation
- Performance status (Zubrod / ECOG-WHO scale)less than or equal to 1 and life expectancy of greater than three months, within 2 weeks of surgery.
- Women of child-bearing potential must have a negative urine or serum pregnancy test within 2 weeks of surgery.
- Signed written informed consent.
Pre-Surgery Exclusion Criteria:
- Prior chemo-, hormonal, immuno- or radiotherapy for renal cell cancer;
- History of primary or secondary immunodeficiency, or patients using immunosuppressive drugs, e.g. systemic corticosteroids, cyclosporin A;
- Current malignancies at other sites or previous other cancer within the last 5 years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin;
- Embolization of the renal artery prior to nephrectomy;
- Known distant metastases;
- Active, uncontrolled infection or other serious medical illnesses.
Eligibility Assessment:
(between 2 weeks pre- and 4 weeks post-surgery)
Prior to randomization and entry into the tumor evaluation phase, all subjects must undergo testing to confirm that they are free of distant metastatic disease, and that they meet all other criteria.
Eligibility Criteria which must be assessed and confirmed prior to randomization:
- No evidence of metastatic or residual renal carcinoma as documented by all of the following: abdominal/pelvis CT scan; chest CT scan; and brain CT or MRI scan.
- Provide Antigenics with greater than or equal to 7 grams of viable tumor tissue
- Adequate bone marrow function.
- Adequate renal and hepatic function.
- Adequate cardiac function.
- Signed written informed consent.
- Patients must be willing to be followed during the course of tumor evaluation and follow-up phases.
- Male or female patients of child producing potential must agree to use adequate contraception during the treatment/observation phase of the study.
- Patients must not use any other investigational drug for four weeks prior to the start of the tumor evaluation phase and throughout the tumor evaluation phase of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-100-12 Part I
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
Clinical Trials on autologous human tumor-derived HSPPC-96
-
Agenus Inc.CompletedLymphoma, Follicular | Lymphoma, Small LymphocyticUnited States
-
Agenus Inc.Terminated
-
Agenus Inc.TerminatedRenal Cell CarcinomaUnited States, Canada
-
Ann & Robert H Lurie Children's Hospital of ChicagoNorthwestern UniversityTerminatedGlioblastoma Multiforme | Ependymoma | Anaplastic Ependymoma | Astrocytoma, Grade III | Clear Cell EpendymomaUnited States
-
Genzyme, a Sanofi CompanyCompletedCarcinoma, Renal CellUnited States
-
Aryn KnightThe University of Texas Health Science Center, Houston; Baylor College of Medicine and other collaboratorsWithdrawnArterial Ischemic Stroke (AIS) in ChildrenUnited States
-
University of FloridaImmunomic Therapeutics, Inc.Terminated
-
Walter J. StorkusNational Cancer Institute (NCI)Completed
-
BonusBio Group LtdCompletedBone Void in the Maxillofacial AreaIsrael
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Iovance Biotherapeutics, Inc.Active, not recruitingMalignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditionsUnited States